Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and

Mar 29, 2021

-- NEXPOVIO is the First and Only Nuclear Export Inhibitor Authorized by the European Commission -- -- Second European Regulatory Filing Based on Phase 3 BOSTON Data Expected by April 2021 --

Posted by Karyopharm Therapeutics

https://investors.karyopharm.com/2021-03-29-Karyopharm-Receives-Conditional-Marketing-Authorization-from-the-European-Commission-for-NEXPOVIO-R-selinexor-in-Combination-with-Dexamethasone-for-the-Treatment-of-Adult-Patients-with-Relapsed-and-or-Refractory-Multiple-Myeloma

See all Member News